As per the research report, the size of the Asia Pacific Schizoaffective Disorders Treatment Market is valued at USD xx billion in 2019 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2024, during the forecast period 2019-2024.
Schizoaffective Disorder is a mental disorder which is characterized by deregulated emotions and thought processes and. The diagnosis is made when the person has features of both a mood disorder—either bipolar disorder or depression, and schizophrenia but does not meet the diagnostic criteria for either alone strictly. The bipolar type is distinguished by symptoms of hypomania, mania, or mixed episode; the depressive type only by symptoms of depression. Common symptoms of the disorder include paranoid delusions, hallucinations, and disorganized thinking and speech. The onset of symptoms usually begins in young times of adulthood, presently with an uncertain lifetime prevalence since the disorder was redefined in DSM-IV. Diagnosis is based on the person's reported experiences observed behaviour.
Neurobiology, genetics, early and current environment, social, behavioural, and experiential components appear to be important contributory factors; some prescription and recreational drugs may worsen or cause symptoms. People with schizoaffective disorder are likely to have co-occurring conditions, including substance use disorder and anxiety disorders. Social problems such as long-term unemployment, homelessness and poverty are common. The average life expectancy of people with the disorder is less than those without it, due to rise of problems related to physical health from an absence of health promoting behaviours including a higher suicide rate and a sedentary lifestyle.
The driving factors of Asia Pacific Schizoaffective Disorders Treatment market are rapidly rising sedentary life style, increasing healthcare spending, growing prevalence of chronic diseases, availability of advanced healthcare treatments and increasing awareness about schizoaffective disorders. While on the other hand, stringent regulatory approval procedures, social stigma associated with schizoaffective disorders, and lack of diagnosis at right time are some of the factors that are constraining the growth of the Asia Pacific schizoaffective disorders treatment market.
This research report segmented and sub-segmented into the following categories:
Asia Pacific has the third largest market for schizoaffective disorders treatment by share. It is also the fastest growing region in the world. Factors such as growing healthcare spending and rising prevalence of chronic diseases is expected to drive the market growth in the region.
The Top companies leading in the APAC Schizoaffective Disorders Treatment Market profiled in the report are Merz Pharma GmbH & Co. KGaA., Eli Lilliy and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Antipsychotics
5.1.1.1 Aripriprazole
5.1.1.2 Clozapine
5.1.1.3 Haloperidol
5.1.1.4 Risperidone
5.1.1.5 Olanzapine
5.1.1.6 Others
5.1.2 Mood Stabilisers
5.1.2.1 Divalproex
5.1.2.2 Lithium
5.1.2.3 Others
5.1.3 Antidepressants
5.1.3.1 Desvenlafaxine
5.1.3.2 Fluoxetine
5.1.3.3 Escitalopram
5.1.3.4 Others
5.1.4 Anticonvulsants
5.1.4.1 Valproate
5.1.4.2 Carbamazepine
5.1.4.3 Others
5.1.5 Psychotherapy
5.1.5.1 Group Therapy
5.1.5.2 Psychotherapy & Counselling
5.1.5.3 Others
5.1.6 Y-o-Y Growth Analysis, By Treatment
5.1.7 Market Attractiveness Analysis, By Treatment
5.1.8 Market Share Analysis, By Treatment
5.2 Cause of Disorder
5.2.1 Genetic Factors
5.2.2 Chemical Factors
5.2.3 Environmental Factors
5.2.4 Y-o-Y Growth Analysis, By Cause of Disorder
5.2.5 Market Attractiveness Analysis, By Cause of Disorder
5.2.6 Market Share Analysis, By Cause of Disorder
5.3 Type
5.3.1 Manic Type
5.3.2 Depressive Type
5.3.3 Mixed Type
5.3.4 Schizoaffective Disorders
5.3.5 Y-o-Y Growth Analysis, By Type
5.3.6 Market Attractiveness Analysis, By Type
5.3.7 Market Share Analysis, By Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Treatment
6.1.3.2 By Cause of Disorder
6.1.3.3 By Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Treatment
6.1.4.2 By Cause of Disorder
6.1.4.3 By Type
6.1.5 Market Share Analysis
6.1.5.1 By Treatment
6.1.5.2 By Cause of Disorder
6.1.5.3 By Type
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Merz Pharma GmbH & Co. KGaA.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Eli Lilliy and Company
8.3 Elan Pharmaceuticals
8.4 Ciba Pharmaceuticals
8.5 Abbott Pharmaceuticals
8.6 AstraZeneca plc
8.7 Janssen-Cilag Pty Limited
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
